NUR 641 Topic 7 DQ 2

Sample Answer for NUR 641 Topic 7 DQ 2 Included After Question

Description:

Select a medication used in evidence-based treatment guidelines for the condition chosen in the first discussion question. Share the mechanism of action of this medication and hints for monitoring, side effects, and drug interactions of which one should be aware. Make sure that you select a different medication than your peers. Include the name of the medication in the subject line so that the medications can be followed. Include your references in APA style.

A Sample Answer For the Assignment: NUR 641 Topic 7 DQ 2

Title: NUR 641 Topic 7 DQ 2

Multiple sclerosis is treated using several drugs. The drug indication depends on the clinical presentation of the condition. Interferon-β-1a (Avonex) is one of the drugs commonly used in the treatment of the condition. The drug is effective in the management of the relapsing-remitting form of the multiple sclerosis disorder (Dendrou, Fugger, & Friese, 2015). It helps in the reduction of the relapse rates and alleviates the severity of the relapse as well as delaying the disease progression. The recommended dosage should be 30mg per week. The active component of AVONEX drug is interferon beta-1a (Dendrou, Fugger, & Friese, 2015). The component regulates inflammatory responses and thus preventing the production of autoimmune cells. Multiple sclerosis is pathophysiology associated with the ability of the body to produce immune cells that attack the own nerve cells (Whalen, 2014). Therefore, by regulating the immune response, the drug prevents the production of antibodies that attack own nerve cells. The drug binds to the specific immune response receptors; though, this exact mechanism of action is not yet fully understood.

The common side effects associated with the drug include depression, suicide, and hepatic injury. Therefore, caution must be taken to consume the recommended dosage. In addition, patients using Interferon-β-1a (Avonex) are at risk of developing decreased peripheral blood count (Huang, Chen, & Zhang, 2017). Patients on the medication should be monitored regularly and the associated side effects addressed in time. Patients should also be advised to report depression and suicidal symptoms immediately before developing severe psychotic symptoms. Under such cases, the Interferon-β-1a (Avonex) therapy should be ceased. In as much as the drug has various side effects, maintaining low dosage improves the therapeutic efficacy. Therefore, this is the best pharmacotherapeutic intervention for managing multiple sclerosis.

References

Dendrou, C. A., Fugger, L., & Friese, M. A. (2015). Immunopathology of multiple sclerosis. Nature Reviews Immunology15(9), 545.

Huang, W. J., Chen, W. W., & Zhang, X. (2017). Multiple sclerosis: pathology, diagnosis, and treatments. Experimental and therapeutic medicine13(6), 3163-3166.

Whalen, K. (2014). Lippincott’s illustrated reviews: Pharmacology (6th ed.). Philadelphia, PA: Lippincott Williams & Wilkens. ISBN-13: 9781451191776